These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33032512)

  • 1. Editorial on Prevalence, Diagnosis and Treatment with 3 Different Statins of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?
    Muzurović E; Smolović B; Vujošević S; Petakov M
    Curr Vasc Pharmacol; 2021; 19(5):582-584. PubMed ID: 33032512
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?
    Sfikas G; Psallas M; Koumaras C; Imprialos K; Perdikakis E; Doumas M; Giouleme O; Karagiannis A; Athyros VG
    Curr Vasc Pharmacol; 2021; 19(5):572-581. PubMed ID: 33059580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis.
    Athyros VG; Katsiki N; Doumas M
    Curr Vasc Pharmacol; 2018 Jan; 16(2):104-106. PubMed ID: 29210655
    [No Abstract]   [Full Text] [Related]  

  • 4. Statins and Non-Alcoholic Fatty Liver Disease Progression: Further Comments.
    Athyros VG; Koumaras C; Sfikas G
    Curr Vasc Pharmacol; 2021; 19(6):673-674. PubMed ID: 33327917
    [No Abstract]   [Full Text] [Related]  

  • 5. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality.
    Athyros VG; Doumas M
    Curr Vasc Pharmacol; 2018; 16(3):206-208. PubMed ID: 29598814
    [No Abstract]   [Full Text] [Related]  

  • 7. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
    Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
    Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
    Doumas M; Imprialos K; Stavropoulos K; Athyros VG
    Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease and statins.
    Tziomalos K; Athyros VG; Paschos P; Karagiannis A
    Metabolism; 2015 Oct; 64(10):1215-23. PubMed ID: 26234727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease.
    Pastori D; Polimeni L; Baratta F; Pani A; Del Ben M; Angelico F
    Dig Liver Dis; 2015 Jan; 47(1):4-11. PubMed ID: 25224698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAFLD and Statins.
    Athyros VG; Katsiki N; Mikhailidis DP
    Dig Dis Sci; 2020 Oct; 65(10):3052-3053. PubMed ID: 32797344
    [No Abstract]   [Full Text] [Related]  

  • 14. [Non-alcoholic liver disease - diagnosis and treatment].
    Sarosiekjeznach-Steinhagen A; Ostrowska J; Czerwonogrodzka-Senczyna A; Boniecka I
    Pol Merkur Lekarski; 2017 Nov; 43(257):237-242. PubMed ID: 29231919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial: statin use in patients with NAFLD-safety concerns, decreased awareness or both?
    Mallet M; Pais R
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1499-1500. PubMed ID: 34741325
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed?
    Athyros VG; Katsiki N; Mikhailidis DP
    Curr Vasc Pharmacol; 2016; 14(4):313-5. PubMed ID: 27173023
    [No Abstract]   [Full Text] [Related]  

  • 17. Statin use and non-alcoholic steatohepatitis in at risk individuals.
    Dongiovanni P; Petta S; Mannisto V; Mancina RM; Pipitone R; Karja V; Maggioni M; Kakela P; Wiklund O; Mozzi E; Grimaudo S; Kaminska D; Rametta R; Craxi A; Fargion S; Nobili V; Romeo S; Pihlajamaki J; Valenti L
    J Hepatol; 2015 Sep; 63(3):705-12. PubMed ID: 25980762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modern approach to the clinical management of non-alcoholic fatty liver disease.
    Del Ben M; Polimeni L; Baratta F; Pastori D; Loffredo L; Angelico F
    World J Gastroenterol; 2014 Jul; 20(26):8341-50. PubMed ID: 25024593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Position statement on the diagnosis and management of non-alcoholic fatty liver disease.
    Alswat KA; Fallatah HI; Al-Judaibi B; Elsiesy HA; Al-Hamoudi WK; Qutub AN; Alturaify N; Al-Osaimi A
    Saudi Med J; 2019 Jun; 40(6):531-540. PubMed ID: 31219486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
    Papademetriou M; Athyros VG; Geladari E; Doumas M; Tsioufis C; Papademetriou V
    Curr Vasc Pharmacol; 2018; 16(3):254-268. PubMed ID: 28676027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.